Phio Pharmaceuticals Corp-Naples Lunch 10/28/2026

Phio Pharmaceuticals Corp Presentation-Please register to attend **Due to limited seating, please make sure each individual registers accordingly. You will not be permitted to attend the event without proper registration. Phio Pharmaceuticals Corp (NASDAQ: PHIO) Wednesday, October 28, 2026 Fleming's Prime Steakhouse & Wine Bar 8985 Tamiami Trail N Naples, FL 34108 Promptly at 12:00 PM Join Phio Pharmaceuticals Corp for this exclusive corporate presentation, followed by a Q & A session moderated by Bear Creek Capital, featuring questions taken from the audience. We hope you can join our presentation About Phio Phamaceuticals Corp Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers. In The News Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 12:00 p.m. to 1:30 p.m. – Presentation and Lunch Contact: Raymond Oliver CEO, Bear Creek Capital 321-439-2120 [email protected]